Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W M D

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
Digestive Diseases and Sciences|April 9, 2024
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI TrialReinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, et al.
The Lancet. Gastroenterology & Hepatology|February 3, 2023
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trialReinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, et al.
Journal of Crohn'S & Colitis|December 15, 2022
Exposure to Thioguanine During 117 Pregnancies in Women With Inflammatory Bowel DiseaseFemke Crouwel, Melek Simsek, Marjon A de Boer, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
Digestive Diseases and Sciences|April 9, 2024
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI TrialReinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, et al.
The Lancet. Gastroenterology & Hepatology|February 3, 2023
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trialReinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, et al.
Journal of Crohn'S & Colitis|December 15, 2022
Exposure to Thioguanine During 117 Pregnancies in Women With Inflammatory Bowel DiseaseFemke Crouwel, Melek Simsek, Marjon A de Boer, et al.
Pageof 5